Scinovex
articleTop 1% cited

Prognostic markers in triple‐negative breast cancer

Cancer · 2006 · Vol. 109(1) · pp. 25–32
Emad A. RakhaMaysa E. El‐SayedAndrew R. GreenAndrew H.S. LeeJ.F.R. RobertsonIan O. Ellis

Abstract

The authors concluded that assessment of androgen receptor and basal phenotype, in addition to the established pathologic variables, mainly lymph node status and tumor size, can be used to select high-risk and low-risk patients at the time of primary surgery and can provide valuable information on treatment options in these triple-negative tumors.

HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer-related Molecular PathwaysMedicineTriple-negative breast cancerCancerBreast cancerOncologyTriple negativeInternal medicine

MeSH terms

AdultAgedBreast NeoplasmsFemaleFollow-Up StudiesHumansImmunohistochemistryMiddle AgedPhenotypePrognosisReceptors, AndrogenReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorCadherins
Citations
1,276
FWCI
27.29
field-weighted impact
References
50
Percentile
100%
vs. same field & year
Citations per year
Cited by
Mechanisms of immune evasion in breast cancer
BMC Cancer · 2018 · 311 citations
Triple negative breast cancer: unmet medical needs
Breast Cancer Research and Treatment · 2010 · 325 citations
Role of epidermal growth factor receptor in breast cancer
Breast Cancer Research and Treatment · 2012 · 786 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.